| Notes: Complete this activity and you will be able to name and describe the four principal types of therapy utilized in the treatment of cancer, list two cellular characteristics that affect prognosis, identify the major side effects of various treatment modality, describe the nursing implications of each treatment modality, and define the goals of cancer treatment. |
| Notes: The authors of this course explain how polymerization causes sickling, show how vaso-occlusion and hemolytic anemia contribute to sickle cell crises, identify the signs and symptoms and appropriate treatment of an aplastic crisis, splenic sequestration, sepsis, and vaso-occlusive/pain crisis, and discuss the age-related differences of morbidity and mortality in sickle cell anemia patients. |
| Notes: Carol S. Viele, RN, MS, presents “Overview of Updated Treatment Options for AML,” and Kathleen Shannon-Dorcy, RN, MN, presents “Nursing Implications: Management of Treatment.” This program was designed “for oncology nurses who desire a deeper understanding of the fundamental differences between novel treatment approaches and standard chemotherapy for patients with AML.” |
| Notes: Scroll down the alphabetized list of course until you see “Melanoma;” click on “View Course” to access the course materials. When you have completed the readings, return to the course catalog and click on “Take Test” to fill out the post-test and pay for credit. Registration is required. Participants who successfully complete this course will be better able to identify the signs and symptoms of melanoma, evaluate various methods of treatment and their side effects, and teach skin self-examination. |
| Notes: Nurses interested in learning more about the use of hormonal therapy in the treatment of nonmetastatic prostate cancer should participate in this online CME program. The resources at this site discuss the epidemiology of prostate cancer in the United States, explain the use of the prostate-specific antigen (PSA) blood test as an aid in detecting prostate cancer, list the treatment options available for nonmetastatic prostate cancer, including hormonal therapy, identify the common adverse effects associated with various treatment modalities, and describe the nurse’s role in role in preventing prostate cancer and disease progression/recurrence. |
| Notes: The three presentations that make up this activity, “Neutropenia: Risk Assessment and Management,” “The Anemia of Cancer: Overview for Nurses,” and “Hematopoietic Support: Special Populations and Guidelines for Use,” identify the risk factors for neutropenia in the patient with cancer, discuss innovative measures in managing neutropenia in the patient with cancer, discuss the mechanism of action of growth factors in development for neutropenia and anemia, and summarize the efficacy of future growth factors for the patient with cancer. |
| Notes: This course identifies the incidence, age, gender, and racial distribution of colorectal cancer in the United States, discusses current strategies for the prevention of colorectal cancer, delineates the roles and responsibilities of nurses in the early detection of colorectal cancer, describes the three staging systems used in colorectal cancer and their relationship to prognosis, identifies nursing roles in surgery and adjuvant therapy, including toxicities and their management, and evaluates palliative interventions for patients with advanced disease. |
| Notes: This article lists the risk factors for breast cancer used in the National Cancer Institute Breast Cancer Risk Assessment Tool, reviews the breast cancer risks associated with hormone replacement therapy, discusses possible screening recommendations for high-risk women, identifies the limitations of breast self-examination, stresses the importance of proper clinical breast-examination techniques, provides an overview of the benefits and criticisms of mammographic screening, and summarizes the screening recommendations of major U.S. organizations. |
| Notes: Medical oncologists and other health care professionals involved in the treatment of patients with cancer will be interested in this activity that identifies the mechanism of action, pharmacology, and potential therapeutic applications of antisense oligonucleotides in oncology, lists the clinical efficacy data and ongoing trials with an antisense molecule targeted to protein kinase C-alpha, explains the mechanism of action and clinical activity of pemetrexed, and discusses the potential applications of genomic and proteomic technology in individualizing therapy for patients with solid tumors. |
| Notes: There are five presentations included in this activity: “Current Options in Hormonal Therapy,” “Sequencing the Aromatase Inhibitors: Does It Make a Difference?” “Implications of Anti-Aromatase Structural Differences,” “Moving Anti-Aromatase Agents in to the Adjuvant Setting,” and “Prevention Strategies With Anti-Aromatase Agents.” Together they discuss new strategies for the sequencing of hormonal agents, explore the evolving role of hormonal therapy in the adjuvant treatment and chemoprevention settings, and the structural differences of and long-term effects and tolerability of therapy with anti-aromatase agents. |
| Notes: Anthony Lucci, Jr., MD, presents “Occult Micrometastases in the Sentinel Node: Identifying Prognostic Significance,” Richard J. Cote, MD, FRCPath presents “Occult Metastases in Bone Marrow Cells: Role in Early Detection and Prognosis,” Jenny C. Chang, MD presents “Predicting Response and Resistance to Endocrine and Cytotoxic Therapy,” and Matthew J. C. Ellis, MD, PhD presents “Gene Array Expression: Detecting Response and Resistance to Aromatase Inhibition.” |
| Notes: Successfully complete this online CME course to familiarize yourself with the historical use of anthracycline therapy for the treatment of breast cancer, be able to identify the optimal anthracycline regimens for high-risk patients in the adjuvant setting, learn about the development of long-term adverse events in anthracycline-treated patients, and learn about the use of novel agents for the treatment of refractory breast cancer. |
| Notes: The three webcasts archived at this site, “Integration of Taxanes in the Treatment of Gastric Cancer,” “Biochemically Synergistic Chemotherapy for Advanced Pancreatic Cancer,” and “The Development of Cell Cycle Inhibitors for the Treatment of Gastrointestinal Cancer,” discuss the emerging therapies that may provide enhanced therapeutic options for management of patients with complex gastrointestinal cancers. |
| Notes: Watch this multimedia CME presentation for descriptions of the familial and hereditary traits and physical symptoms in female patients with breast cancer, discussion of recent clinical data on the neucleoside analog gemcitabine in the treatment of metastatic breast cancer, evaluation of the efficacy of gemcitabine treatment follwoing anthracycline/taxane therapy, and a list of the quality of life factors that should be taken into consideration when the patient and health care team decide on this form of treatment. |
| Notes: This CME resource discusses the prevalence of urinary incontinence (UI) in the United States, along with the relative frequencies of the different types of UI, describes the clinical presentation of the different types of UI, identifies the basic diagnostic work-up necessary to distinguish the different types of UI, discusses available treatments, and those currently under development, for stress incontinence, and explains the pharmacological and physiological basis for each treatment. |
| Notes: The five case studies that make up this activity discuss the role of sequential single chemotherapeutic agents and combination chemotherapy in metastatic breast cancer, describe the options for hormonal therapy in the management of breast cancer, and discuss the role of trastuzumab when used in combination with chemotherapy for patients with metastatic breast cancer. Sample study titles include Sequential Single Agents vs Combination Chemotherapy” and “Receptor-Positive Disease: Hormones or Chemotherapy?” |
| Notes: This activity describes the causes of and conditions associated with cancer pain, discusses intercostobrachial neuralgia as a complication of breast cancer treatment, identifies useful methods of diagnosing specific painful complications of cancer, evaluates pharmacologic, therapeutic, and toxicologic principles involved in relieving cancer pain, and defines specific terms that describe elements of cancer pain and its control. |
| Notes: Urologists treating patients with benign prostatic hyperplasia (BPH) will find much of value in this program, including a description of the basic physiology of alpha-adrenergic neural transmission, information on the basic principles of the use of alpha-adrenergic blockade in the treatment of BPH, a description of the presentation of mild to severe BPH for diagnosis, and details about the appropriate treatments for the various presentations of BPH. |
| Notes: Created from presentations given at the 25th Annual San Antonio Breast Cancer Symposium, this online CME activity features four sections that discuss the latest findings in breast cancer biology and treatment. Nicholas J. Robert, MD, offers “Update on Adjuvant Endocrine Therapy: Focus on Anastrozole, Tamoxifen, and Goserelin.” The prolific Kathleen I. Pritchard, MD, FRCPC, is the author of the other three sections: “New Prognostic and Predictive Factors: Are They Ready for Clinical Use?” “Aromatase Inhibitors: The State of the Art,” and “The Role of Growth Factors in Endocrine Resistance and Independence in Breast Cancer.” |
| Notes: The articles at this site review the molecular mechanisms and potential benefits of new drugs under development, evaluate the use of new biotechnologies to improve diagnosis and prognosis for cancer patients, and interpret the results of trials performed to test efficacy and toxicity of novel targeted therapies. |
| Notes: Complete this activity for information on tailoring treatment for patients with breast cancer, controversies in the adjuvant treatment of breast cancer, targeted therapies in the treatment of non-small cell lung cancer, multimodality treatments for mesothelioma, the use of combination therapy in the treatment of metastatic colorectal cancer, and the evidence for the usefulness of “psycho-oncology.” |
|
 |
Departments
Internet Listings
|
